Sanjivani Paranteral released its investor presentation for the first quarter of FY27, showcasing a strong recovery.

Consolidated revenue from operations grew to ₹23.84 crore, a 33.81% increase year-over-year.

Profit after tax jumped 43.94% to ₹2.49 crore, with EBITDA at ₹4.32 crore (18.01% margin). Exports contributed ₹17.61 crore, demonstrating resilience after recent shipping disruptions through re-routed supply chains.

The new IV-fluid plant is ramping up, contributing ₹4.38 crore, and is expected to drive significant growth in FY27 alongside established injectables and oral segments.

The company aims for ₹140-150 crore revenue in FY27 across all verticals.